Karine E. Ronan

International Breast Cancer Trials and Optimal Sequence of Treatment

Uri Bender, Karine E. Ronan, Eitan Amir

ca (code pays fourni par la source)

Achieving Pregnancy After Early Hormone Receptor-Positive Breast Cancer: Recent Evidence and Clinical Considerations

Karine E. Ronan, Janice Maria Walshe

An increasing number of young women with hormone receptor-positive (HR+) early breast cancer desire pregnancy after treatment. Prolonged adjuvant endocrine therapy, concerns regarding recurrence risk, and treatment-related fertility decline have historically complicated reproductive decision-making in this population. This narrative review synthesizes current …

ca, ie (code pays fourni par la source)

Abstract P2-12-12: Impact of the addition of pembrolizumab to neoadjuvant chemotherapy in triple negative breast cancer in Ireland: a retrospective, multi-centre, real-world study

Karine E. Ronan, Karolina Weiner‐Gorzel, Benjamin Mathewson, Lisa Mary Prior et autres

Abstract Background: The 60-month follow up data from the phase III KEYNOTE 522 (KN522) trial reported that the addition of pembrolizumab (pembro) to chemotherapy improved event free survival (EFS) and increased the rate of pathological complete response (pCR).1 As a result, the …

An analysis of compassionate access programmes for novel oncology drugs

S. Kelly, Karine E. Ronan, Mohammed Zameer, Jennifer Brown et autres

BACKGROUND: Despite the rise in the number of approved novel oncology drugs, just over half of all new cancer medicines approved by the EMA between 2017 and 2021 were granted reimbursement in Ireland by the HSE. Compassionate access programmes (CAPs) are a …

ie (code pays fourni par la source)

Implementing a drug interaction protocol for oral systemic anti-cancer therapy with focus on CDK4/6 inhibitors.

Calvin R. Flynn, Eileen M. McMahon, Shahid Iqbal, Karen McLoughlin et autres

302 Background: Oral anti-cancer therapies (OACTs) are being increasingly used. Despite their convenience, OACTs introduce challenges with adherence, prescribing errors, and high incidence of drug-drug interactions (DDIs). Currently, there are limited guidelines for DDI checking. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have revolutionized …

ie (code pays fourni par la source)

Personalised app-based information for patients with breast cancer: A pilot study to assess the efficacy and usability of the Answers 4 Cancers app.

Annemarie Fay, Michelle L. Matthews, Karine E. Ronan, Susan Geraghty et autres

e13796 Background: While most Irish oncology patients (pts) report searching for information online, they encounter challenges finding accurate, illness-specific information and understanding the content. Irish oncology pts typically use international online resources due to limited dedicated Irish sources. Information from the clinic …

ie (code pays fourni par la source)

Frequency of next-generation sequencing, prevalence of targetable mutations and response to targeted therapies amongst patients with metastatic urothelial cancer in Ireland: a multi-centre retrospective study of real-world data

Karine E. Ronan, Emmet Jordan, Christine E. Leonard, Ray McDermott

ie (code pays fourni par la source)

2138P Time toxicity of palliative chemotherapy in a geriatric oncology population

Cornelius C. Cronin, D.T. O'Sullivan, Karine E. Ronan, M. Hannan et autres

ie (code pays fourni par la source)

A retrospective single-centre analysis of the prevalence of statin use in geriatric oncology: Is there a role for cessation?

Darragh Thomas O'Sullivan, Anne M. Horgan, Rachel Clarke, Karine E. Ronan et autres

e24016 Background: Statins have become ubiquitous in medicine. There is a myriad of indications, and the duration of treatment required for efficacy is measured in years. There is a need for clarity on their role in geriatric oncology and when to de-prescribe. …

ie (code pays fourni par la source)

249P A retrospective review of patients receiving trastuzumab deruxtecan across five centres in Ireland with a subgroup analysis of patients with CNS involvement assessing response in the CNS

Conleth Murphy, Karine E. Ronan, Jemma Buchalter, Ruth H. Keogh et autres

Approximately 30%-%0% of patients with HER2-positive breast cancer will develop central nervous system (CNS) metastasis. Trastuzumab deruxtecan (T-DXd) is known to have clinically relevant activity in HER2- positive metastatic breast cancer (MBC) patients who have progressed on prevsious lines of treatment. DESTINY-Breast01 …

ie (code pays fourni par la source)

Paraneoplastic syndromes in esophageal cancer—a narrative review

Colm Mac Eochagáin, Karine E. Ronan, Calvin R. Flynn, Zara Togher et autres

Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise

Brian Bird, Kenneth Nally, Karine E. Ronan, Gerard A. Clarke et autres

Immune checkpoint inhibitors are monoclonal antibodies that are used to treat over one in three cancer patients. While they have changed the natural history of disease, prolonging life and preserving quality of life, they are highly active in less than 40% of …

ie (code pays fourni par la source)